Bioeclipse Therapeutics Inc., of South San Francisco, said it raised $7.7 million in its series A-1 financing round, which was led by Revelis Capital Group LLC, with participation from Tsingyuan Ventures, DEFTA Partners, TSVC (TEEC Angel Fund) and Plum Alley.